27 October 2020 : Review article
Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review
Ashraf Imam1ADEFG, Sadi A. Abukhalaf1ABCDEF, Hadar Merhav1CDFG, Samir Abu-Gazala1ABDG, Oded Cohen-Arazi1BCEG, Alon Josef Pikarsky1DEFG, Rifaat Safadi2EFG, Abed Khalaileh1AEFG*DOI: 10.12659/AOT.926196
Ann Transplant 2020; 25:e926196
Table 5 Management and outcomes of all available reported liver transplant recipients infected with COVID-19.
| Study | ISM management | COVID-19 targeted management | ICU | Complications | Outcome |
|---|---|---|---|---|---|
| Zhong | Tac held; IVMP | Oseltamivir, Abx, | Yes | None | Recovered, 40d |
| Liu | Tac held; IVMP | Umifenovir, lopinavir/ritonavir, IVIG, Abx, INF-a | No | None | Recovered, 35d |
| Huang | Reduced Tac, MMF; IVMP | Umifenovir, lopinavir/ritonavir, Abx, INF-a | Respiratory failure, AKI, MOF, | Died, 45d | |
| Qin | No change | Oseltamivir, IVIG, rh-GCSF, Abx | Recovered, 53d | ||
| Morand | Reduced Tac | Paracetamol | Recovered, 11d | ||
| Lagana | Reduced MMF | Hydroxychloroquine | Yes | None | Hospitalized, 16d |
| Kates | No change | Yes | AKI | Recovered, 6d | |
| Hammami | No change | Hydroxychloroquine, Azithromycin, Abx, tocilizumab | Recovered, 16d | ||
| Fernández-Ruiz | Held EVE and start Tac, MMF | Hydroxychloroquine, lopinavir/ritonavir | Recovered, 19d | ||
| Held EVE, MMF and start Tac | Hydroxychloroquine, lopinavir/ritonavir, IFN-b | AKI, ARDS, | Died, 7d | ||
| No change | Hydroxychloroquine, IFN-b | Recovered, 14d | |||
| Held MMF | Yes | ARDS, Refractory shock | Died, 24d | ||
| No change | Hydroxychloroquine | Recovered, 15d | |||
| No change | Recovered, 18d | ||||
| Donato | 6 Recovered, 2 Hospitalized |